Gustavo Monnerat, Deputy Editor at The Lancet, shared a post on LinkedIn:
“A new Lancet Regional Health – Europe series offers a very comprehensive view at where cancer therapy may be heading.
Across four papers, the series examines:
- cell therapy for solid tumours
- antibody-drug conjugates
- bispecific and multispecific antibodies
- oncolytic virapplys and neoantigen vaccines
For anyone interested in where systemic cancer treatment may be heading over the next few years, this series is worth reading.
Which of these four areas do you consider is most likely to reshape routine oncology practice first?”
More posts featuring Gustavo Monnerat.
Leave a Reply